A heart failure diagnosis from your cardiologist or physician marks the start of long-term specialist-managed care. Understanding how your medical aid works for this condition — particularly how CDL registrations interact with heart failure treatment — is essential to managing costs sustainably.
The Honest Starting Point
Heart failure itself is not a CDL condition. But the conditions that cause or accompany heart failure — hypertension, diabetes, atrial fibrillation, coronary artery disease — mostly are CDL-listed. Getting CDL registrations right is the single most impactful action you can take for your medical aid costs.
Acute hospital admissions for decompensated heart failure are PMB-funded. Outpatient cardiologist visits, echocardiography, and newer medications (like Entresto) come from your day-to-day benefit or require formulary negotiation.
Step 1: Register All CDL Conditions Immediately
The most important step. If you have any of the following alongside heart failure, they should already be registered on the CDL — if not, do it now:
- Hypertension (CDL) — virtually universal in SA heart failure patients; register immediately
- Type 2 diabetes (CDL) — if present; opens access to CDL-funded SGLT2 inhibitors
- Atrial fibrillation / dysrhythmia (CDL) — if present; register
- Dyslipidaemia (CDL) — if on statin therapy; register
Why this matters: CDL registration means your chronic medications for these conditions are funded from the CDL benefit, not your MSA. This shifts often R2,000–R5,000/month in drug costs off your day-to-day benefit.
CDL registration process: Your cardiologist or GP submits a CDL application to your scheme with diagnosis, medication, and dosing. Call your scheme to get the specific form or process.
Step 2: Understand Your Medication Coverage
ACE inhibitors / ARBs (enalapril, ramipril, lisinopril, losartan, valsartan): Cornerstone HF therapy. Inexpensive generic; CDL-funded via hypertension registration.
Beta-blockers (carvedilol, bisoprolol, metoprolol): Essential in HFrEF. Generic available; CDL-funded via hypertension.
Diuretics (furosemide, spironolactone/eplerenone): Symptom management and remodelling. CDL-funded via hypertension.
Sacubitril/valsartan (Entresto): Best-in-class for HFrEF. R1,500–R2,800/month. Not CDL. Check your scheme formulary. If not covered, your cardiologist should motivate for non-formulary approval — this is a standard cardiology process and often succeeds with a well-written clinical motivation.
SGLT2 inhibitors (dapagliflozin/empagliflozin): Have proven mortality benefit in HF even without diabetes. If you have type 2 diabetes (CDL), SGLT2 inhibitors are CDL-fundable medications that also benefit your heart failure. If you don't have diabetes, funding is from day-to-day — check formulary.
Call your scheme: "Is sacubitril/valsartan (Entresto) on my formulary? Is dapagliflozin covered for heart failure if I don't have diabetes?"
Step 3: Set Up Your Cardiologist Monitoring Programme
Heart failure requires regular specialist input. A standard monitoring programme for stable heart failure: - Cardiologist: every 3–6 months (more frequently when unstable or adjusting therapy) - Echocardiogram: every 12–24 months, or more frequently after medication changes - Blood tests (electrolytes, renal function, BNP) — every 3–6 months - 24-hour Holter monitor (if AF/arrhythmia co-present) — annually
What to confirm with your scheme: - What is my specialist sub-limit (annual rand cap on specialist consultations)? - Is my cardiologist on the DSP panel? - Is echocardiography covered under my radiology or cardiology benefit, and how many per year? - Are BNP blood tests on my pathology formulary?
Step 4: Understand When Hospitalisation Is Likely — and Plan for It
Heart failure has an average hospitalisation rate of ~30% per year for patients with moderate-severe disease. Acute decompensated heart failure (ADHF) — sudden worsening of symptoms from fluid overload — is the most common cause.
Your scheme must fund acute HF hospitalisations as PMB. But hospitalisation has financial implications beyond the PMB bed day: - Cardiologist in-hospital billing above tariff — gap cover relevant - Echocardiography during admission — often at scheme tariff during PMB admission - Post-discharge specialist and follow-up costs — from day-to-day
Warning signs of decompensation (go to ER or call your cardiologist urgently): - Sudden increase in weight (>2kg in 48 hours) — fluid accumulation - Worsening breathlessness, especially when lying flat (orthopnoea) or at night (paroxysmal nocturnal dyspnoea) - Increasing ankle/leg swelling - Reduced urine output despite taking diuretics - Sudden severe breathlessness at rest
Step 5: Device Therapy — What Is Covered?
For HFrEF with EF <35% despite optimal medical therapy, device therapy reduces sudden cardiac death risk:
ICD (implantable cardioverter-defibrillator): Defibrillates life-threatening arrhythmias. Covered as PMB under the cardiac arrhythmia DTP. The ICD device costs R60,000–R120,000; the procedure (surgical implant) is in-hospital under the hospital benefit.
CRT (cardiac resynchronisation therapy): Improves coordinated contraction of the ventricles. Covered under cardiac PMB DTP for qualifying patients. More expensive than single-device ICD.
Both require pre-authorisation. Gap cover is relevant for the electrophysiologist/cardiologist shortfall during the implant procedure.
Support Resources
Heart and Stroke Foundation SA: heartfoundation.co.za — patient support and information SADAG (mental health for chronic illness): 0800 567 567 | sadag.org Council for Medical Schemes: 0861 123 267 | www.medicalschemes.co.za
Talk to Eldon
Heart failure management is most cost-effective when CDL registrations are optimised and Entresto access is secured. The Check shows what each plan on our panel pays for this, side by side, and Eldon advises from there.
Optimise your plan for heart failure →